The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNuformix Share News (NFX)

Share Price Information for Nuformix (NFX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.20
Bid: 0.17
Ask: 0.21
Change: 0.01 (5.56%)
Spread: 0.04 (23.529%)
Open: 0.20
High: 0.20
Low: 0.20
Prev. Close: 0.18
NFX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

SMALL-CAP WINNERS & LOSERS: Nuformix jumps as partner inks contract

Tue, 08th Feb 2022 10:52

(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Tuesday.

----------

SMALL-CAP - WINNERS

----------

Nuformix PLC, up 16% at 1.17 pence, 12-month range 0.96p-3.63p. The pharmaceutical development company says partner Oxilio Ltd has signed a significant service contract with Quotient Sciences Ltd to support the formulation development of its cancer drug NXP001. "This arrangement is allowing Oxilio to progress NXP001 without cost to the company whilst we focus on progressing our two lead assets, NXP002 and NXP004," Chair Alastair Riddell says.

----------

Riverstone Energy Ltd, up 5.3% at 532.70p, 12-month range 2.53p-538.00p. Shares in investor in energy companies hit 12-month high as it says it will sell its entire stake in Pipestone Energy Corp for CAD53.0 million, about GBP30.8 million. Riverstone says it will use the proceeds as part of its plan to recommence its share buyback programme. Riverstone said it decided to allocate an additional GBP46 million to the GBP40 million programme launched last May. It already has repurchased 7.7 million shares at a total cost of GBP36 million.

----------

Avon Protection PLC, up 4.7% at 1,154.80p, 12-month range 860.00p-3,660.00p. The personal protection company wins a contract with a maximum value of USD204 million over five years to supply helmets to the US Defence Logistics Agency. Says that initial revenue from the contract expected in its 2024 financial year, following completion of first article testing in 2023. Avon Protection's financial year ends September 30.

----------

Rainbow Rare Earths Ltd, up 3.7% at 17.37p, 12-month range 0.11p-17.50p. The rare earth element miner receives positive results from a test work programme at its Phalaborwa rare-earth minerals project in South Africa. Says results to date have provided it with additional optimisation opportunities to explore, which can reduce both operating and capital costs for the project. The next phase of the test work programme is now underway, which includes a number of trade-off and project optimisation studies, Rainbow says.

----------

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
28 Jul 2022 16:14

EXECUTIVE CHANGES: Cohort co-founder out; Nuformix co-founder back

(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Thursday and not separately reported by Alliance News:

Read more
28 Jul 2022 15:01

EARNINGS UPDATES: Alliance Trust beats benchmark and ups dividend

(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
29 Jun 2022 12:25

IN BRIEF: Nuformix shares rise as progresses with cancer programme

Nuformix PLC - London-based pharmaceutical development firm focused on fibrosis and oncology via drug repurposing - Starts to scale-up the production processes of lead cocrystals for its cancer programme NXP004, focused on the treatment for advanced ovarian cancer. Firm aims to develop new forms of Olaparib, "currently marketed by AstraZeneca PLC, under the Lynparza brand name," Nuformix explains. First approved in 2014 for advanced ovarian cancer, it has since received "similar approvals in breast, pancreatic and prostate cancers with further trials on-going."

Read more
27 Jun 2022 21:51

TRADING UPDATES: Anglo-Eastern Plantations sees palm oil prices rise

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
31 May 2022 12:41

Nuformix Executive Chair Alastair Riddell resigns after one year

(Alliance News) - Nuformix PLC on Tuesday said Executive Chair Alastair Riddell has resigned with immediate effect.

Read more
30 May 2022 11:54

IN BRIEF: Nuformix shares plunge on inconsistent repeat study results

Nuformix PLC - London-based pharmaceutical development firm focused on fibrosis and oncology via drug repurposing - Says the contract research organisation undertaking the final planned pre-clinical study for its NXP002 treatment had a protocol failure, which has voided the study. Says the organisation repeated the study and recorded results that were inconsistent with the first in vivo study at all time points and also with the oral control. Notes that no positive or negative conclusions could be drawn from this study.

Read more
30 May 2022 11:13

SMALL-CAP WINNERS & LOSERS: Foxtons finds new CEO; S4 revenue surges

(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Monday.

Read more
28 Mar 2022 19:18

IN BRIEF: Nuformix NXP004 patent application reaches publication phase

Nuformix PLC - London-based pharmaceutical development firm focused on fibrosis and oncology via drug repurposing - Says patent application for key asset NXP004 had progressed to the publication phase. NXP004 is a new formulation of Olaparib, which is used to treat ovarian, breast and pancreatic cancers currently marketed by FTSE 100-listed AstraZeneca PLC, under the name Lynparza. The patent application, which was made in September 2020, covers new olaparib oxalic acid cocrystals, their therapeutic uses and pharmaceutical compositions containing them. A second patent application was filed last November which remains pending.

Read more
8 Feb 2022 13:58

TRADING UPDATES: Round Hill Music buys Alice In Chains catalogue

TRADING UPDATES: Round Hill Music buys Alice In Chains catalogue

Read more
14 Dec 2021 18:01

TRADING UPDATES: Cohort interim loss widens, Yourgene loss narrows

TRADING UPDATES: Cohort interim loss widens, Yourgene loss narrows

Read more
25 Nov 2021 16:23

IN BRIEF: Nuformix notes positive results for inhaled NXP002 dose

IN BRIEF: Nuformix notes positive results for inhaled NXP002 dose

Read more
12 Nov 2021 12:11

TRADING UPDATES: Princess exits Taco Bell; Nuformix files patent

TRADING UPDATES: Princess exits Taco Bell; Nuformix files patent

Read more
12 Nov 2021 10:54

SMALL-CAP WINNERS & LOSERS: Avon Protection plates face approval delay

SMALL-CAP WINNERS & LOSERS: Avon Protection plates face approval delay

Read more
9 Nov 2021 15:30

CORRECT: Nuformix Chair Alastair Riddell to move to executive chair

CORRECT: Nuformix Chair Alastair Riddell to move to executive chair

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.